Progentos Therapeutics

Veteran Translational Medicine and Clinical Development Leader Joins as Company Prepares to Advance its Lead Program for Remyelination in Multiple Sclerosis to Human Studies.

Aleks Radovic-Moreno, PhD, is a partner at Longwood Fund, where he is involved in building and supporting portfolio companies. Aleks has been a co-founder of several Longwood portfolio companies, including Co-Founder and CEO of Be Biopharma and Co-Founder of Tome Biosciences.

Cassidy Blundell, PhD, is a Partner at Mission BioCapital, investing in early-stage biotechnology companies and supporting portfolio company operations. She serves on the boards of Volnay Therapeutics, ARase Therapeutics, and as an observer at Mediar Therapeutics.

Chris Loose, CEO of Progentos Therapeutics. Developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.

Dmitrij Hristodorov is General Partner at Forbion and core member of the investment team working on new investments across funds and therapeutic areas.

Progentos Therapeutics announced the appointment of Paul Frohna, MD, PhD, as Chief Medical Officer. Dr. Frohna has over 20 years of experience in translational medicine, clinical development, and regulatory affairs.

Nothing to book right now. Check back soon.

Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.

Progentos Therapeutics initiates human trials for **PRO-1562**, an oral drug designed to repair myelin—the protective nerve insulation damaged by multiple sclerosis (MS). Unlike existing treatments that suppress immune attacks, PRO-1562 stimulates the brain’s own repair cells to generate new myelin-producing cells. The biotech, based in Cambridge, Massachusetts, has not yet revealed the drug’s precise mechanism but positions it as a potential breakthrough for relapsing MS patients.

Oct 2026calcoastms.comNews article

Progentos Therapeutics develops therapies to address neurological damage in multiple sclerosis (MS), unlike current treatments that focus only on symptom management. The company’s approach targets repairing the underlying damage caused by the disease. Founded by Chris Loose, PhD, Progentos combines research and innovation to advance precision medicine solutions for MS patients.

Jun 2025Inside Precision MedicineNews article

Progentos secures $65 million in funding to advance small-molecule therapies aimed at inducing remyelination. The company focuses on regenerative treatments for myelin damage, a key factor in multiple sclerosis progression. This investment supports preclinical and clinical development of its pipeline.

May 2024Multiple Sclerosis News TodayNews article

Progentos secures $65 million in funding to advance preclinical research into multiple sclerosis treatments. The company acquires intellectual property developed by Frequency Therapeutics, a regenerative medicine firm that previously delisted from Nasdaq. Progentos now plans to transition the work into clinical trials.

May 2024Endpoints NewsNews article